{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T03:05:51Z","timestamp":1773803151700,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T00:00:00Z","timestamp":1605744000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The aim of this study was to evaluate prognostic factors including surgical, radiographic, and histopathologic analyses in anaplastic oligodendroglioma (AO) patients. We reviewed the electronic records of 95 patients who underwent surgery and were diagnosed with AO for 20\u00a0years. The primary endpoints were progression-free survival (PFS) and overall survival (OS). Univariate and multivariable analyses included clinical, histopathological, and radiographic prognostic factors. Subgroup analysis was performed in isocitrate dehydrogenase (<jats:italic>IDH1\/2)<\/jats:italic>-mutant and 1p\/19q-codeleted patients. The median PFS and OS were 24.7\u00a0months and 50.8\u00a0months, respectively. The 1-, 3-, 5-, and 10-year PFS were 75.8%, 42.9%, 32.4%, and 16.4%, respectively. Furthermore, the 1-, 3-, 5-, and 10-year OS were 98.9%, 76.9%, 42.9%, and 29.7%, respectively. The median PFS and OS of the <jats:italic>IDH1\/2<\/jats:italic>-mutant and 1p\/19q-codeleted patients were 54.2 and 57.8\u00a0months, respectively. In univariate analyses, young age, frontal lobe, weak enhancement, gross total resection (GTR), low Ki-67 index, 1p\/19q codeletion, and <jats:italic>IDH1\/2<\/jats:italic> mutations were associated with a favorable outcome. In multivariable analyses, <jats:italic>IDH1\/2<\/jats:italic> mutation was related to better PFS and OS. In subgroup analysis, GTR was associated with favorable outcomes.<\/jats:p>","DOI":"10.1038\/s41598-020-77228-2","type":"journal-article","created":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T11:03:51Z","timestamp":1605783831000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Survival outcome and prognostic factors in anaplastic oligodendroglioma: a single-institution study of 95 cases"],"prefix":"10.1038","volume":"10","author":[{"given":"Dong-Won","family":"Shin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seungjoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sang Woo","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young Hyun","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seok Ho","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ho Sung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ji Eun","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soo Jeong","family":"Nam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young-Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,11,19]]},"reference":[{"key":"77228_CR1","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","volume":"19","author":"QT Ostrom","year":"2017","unstructured":"Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2010\u20132014. Neuro Oncol. 19, v1\u2013v88. https:\/\/doi.org\/10.1093\/neuonc\/nox158 (2017).","journal-title":"Neuro Oncol."},{"key":"77228_CR2","doi-asserted-by":"publisher","first-page":"467","DOI":"10.3171\/jns.2003.99.3.0467","volume":"99","author":"ER Laws","year":"2003","unstructured":"Laws, E. R. et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J. Neurosurg. 99, 467\u2013473. https:\/\/doi.org\/10.3171\/jns.2003.99.3.0467 (2003).","journal-title":"J. Neurosurg."},{"key":"77228_CR3","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1093\/neuonc\/nor185","volume":"14","author":"S Li","year":"2012","unstructured":"Li, S. et al. Molecular prognostic factors of anaplastic oligodendroglial tumors and its relationship: a single institutional review of 77 patients from China. Neuro Oncol. 14, 109\u2013116. https:\/\/doi.org\/10.1093\/neuonc\/nor185 (2012).","journal-title":"Neuro Oncol."},{"key":"77228_CR4","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1111\/j.1365-2559.2011.04134.x","volume":"60","author":"M Preusser","year":"2012","unstructured":"Preusser, M. et al. Prognostic value of Ki67 index in anaplastic oligodendroglial tumours\u2014a translational study of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Histopathology 60, 885\u2013894. https:\/\/doi.org\/10.1111\/j.1365-2559.2011.04134.x (2012).","journal-title":"Histopathology"},{"key":"77228_CR5","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1093\/neuonc\/nor114","volume":"13","author":"D Scheie","year":"2011","unstructured":"Scheie, D. et al. Prognostic variables in oligodendroglial tumors: a single-institution study of 95 cases. Neuro Oncol. 13, 1225\u20131233. https:\/\/doi.org\/10.1093\/neuonc\/nor114 (2011).","journal-title":"Neuro Oncol."},{"key":"77228_CR6","doi-asserted-by":"publisher","first-page":"e0211513","DOI":"10.1371\/journal.pone.0211513","volume":"14","author":"S Liu","year":"2019","unstructured":"Liu, S., Liu, X., Xiao, Y., Chen, S. & Zhuang, W. Prognostic factors associated with survival in patients with anaplastic oligodendroglioma. PLoS ONE 14, e0211513. https:\/\/doi.org\/10.1371\/journal.pone.0211513 (2019).","journal-title":"PLoS ONE"},{"key":"77228_CR7","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11060-015-1902-2","volume":"125","author":"HC Kang","year":"2015","unstructured":"Kang, H. C. et al. A multicenter study of anaplastic oligodendroglioma: the Korean Radiation Oncology Group Study 13\u201312. J. Neurooncol. 125, 207\u2013215. https:\/\/doi.org\/10.1007\/s11060-015-1902-2 (2015).","journal-title":"J. Neurooncol."},{"key":"77228_CR8","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1038\/s41598-020-59089-x","volume":"10","author":"J Choi","year":"2020","unstructured":"Choi, J. et al. Extent of resection and molecular pathologic subtype are potent prognostic factors of adult WHO grade II glioma. Sci. Rep. 10, 2086. https:\/\/doi.org\/10.1038\/s41598-020-59089-x (2020).","journal-title":"Sci. Rep."},{"key":"77228_CR9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1200\/JCO.2003.06.023","volume":"21","author":"JC Buckner","year":"2003","unstructured":"Buckner, J. C. et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J. Clin. Oncol. 21, 251\u2013255. https:\/\/doi.org\/10.1200\/JCO.2003.06.023 (2003).","journal-title":"J. Clin. Oncol."},{"key":"77228_CR10","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3174\/ajnr.A6358","volume":"41","author":"DJ Leao","year":"2020","unstructured":"Leao, D. J., Craig, P. G., Godoy, L. F., Leite, C. C. & Policeni, B. Response assessment in neuro-oncology criteria for gliomas: practical approach using conventional and advanced techniques. AJNR Am. J. Neuroradiol. 41, 10\u201320. https:\/\/doi.org\/10.3174\/ajnr.A6358 (2020).","journal-title":"AJNR Am. J. Neuroradiol."},{"key":"77228_CR11","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1056\/NEJMoa0808710","volume":"360","author":"H Yan","year":"2009","unstructured":"Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765\u2013773. https:\/\/doi.org\/10.1056\/NEJMoa0808710 (2009).","journal-title":"N. Engl. J. Med."},{"key":"77228_CR12","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1200\/jco.2005.04.6078","volume":"24","author":"MJ van den Bent","year":"2006","unstructured":"van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J. Clin. Oncol. 24, 2715\u20132722. https:\/\/doi.org\/10.1200\/jco.2005.04.6078 (2006).","journal-title":"J. Clin. Oncol."},{"key":"77228_CR13","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1200\/jco.2012.43.2229","volume":"31","author":"MJ van den Bent","year":"2013","unstructured":"van den Bent, M. J. et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. J. Clin. Oncol. 31, 344\u2013350. https:\/\/doi.org\/10.1200\/jco.2012.43.2229 (2013).","journal-title":"J. Clin. Oncol."},{"key":"77228_CR14","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s11060-016-2212-z","volume":"129","author":"JY Shin","year":"2016","unstructured":"Shin, J. Y. & Diaz, A. Z. Utilization and impact of adjuvant therapy in anaplastic oligodendroglioma: an analysis on 1692 patients. J. Neurooncol. 129, 567\u2013575. https:\/\/doi.org\/10.1007\/s11060-016-2212-z (2016).","journal-title":"J. Neurooncol."},{"key":"77228_CR15","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1007\/s11060-019-03261-5","volume":"144","author":"CJ Kinslow","year":"2019","unstructured":"Kinslow, C. J. et al. Extent of resection and survival for oligodendroglioma: a US population-based study. J. Neurooncol. 144, 591\u2013601. https:\/\/doi.org\/10.1007\/s11060-019-03261-5 (2019).","journal-title":"J. Neurooncol."},{"key":"77228_CR16","doi-asserted-by":"publisher","DOI":"10.1093\/neuros\/nyaa037","author":"GM Della Pepa","year":"2020","unstructured":"Della Pepa, G. M. et al. 5-aminolevulinic acid and contrast-enhanced ultrasound: the combination of the two techniques to optimize the extent of resection in glioblastoma surgery. Neurosurgery https:\/\/doi.org\/10.1093\/neuros\/nyaa037 (2020).","journal-title":"Neurosurgery"},{"key":"77228_CR17","doi-asserted-by":"publisher","first-page":"e858","DOI":"10.1016\/j.wneu.2018.09.237","volume":"121","author":"J Byun","year":"2019","unstructured":"Byun, J. et al. Comparison of survival outcomes between partial resection and biopsy for primary glioblastoma: a propensity score-matched study. World Neurosurg. 121, e858\u2013e866. https:\/\/doi.org\/10.1016\/j.wneu.2018.09.237 (2019).","journal-title":"World Neurosurg."},{"key":"77228_CR18","doi-asserted-by":"publisher","first-page":"2394","DOI":"10.1200\/jco.2017.72.6737","volume":"35","author":"MJ van den Bent","year":"2017","unstructured":"van den Bent, M. J., Smits, M., Kros, J. M. & Chang, S. M. Diffuse infiltrating oligodendroglioma and astrocytoma. J. Clin. Oncol. 35, 2394\u20132401. https:\/\/doi.org\/10.1200\/jco.2017.72.6737 (2017).","journal-title":"J. Clin. Oncol."},{"key":"77228_CR19","doi-asserted-by":"publisher","first-page":"20150857","DOI":"10.1259\/bjr.20150857","volume":"89","author":"M Smits","year":"2016","unstructured":"Smits, M. Imaging of oligodendroglioma. Br. J. Radiol. 89, 20150857. https:\/\/doi.org\/10.1259\/bjr.20150857 (2016).","journal-title":"Br. J. Radiol."},{"key":"77228_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.3171\/jns.2006.105.1.34","volume":"105","author":"GE Keles","year":"2006","unstructured":"Keles, G. E. et al. Volumetric extent of resection and residual contrast enhancement on initial surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. J. Neurosurg. 105, 34\u201340. https:\/\/doi.org\/10.3171\/jns.2006.105.1.34 (2006).","journal-title":"J. Neurosurg."},{"key":"77228_CR21","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1215\/15228517-2007-023","volume":"9","author":"DA Lim","year":"2007","unstructured":"Lim, D. A. et al. Relationship of glioblastoma multiforme to neural stem cell regions predicts invasive and multifocal tumor phenotype. Neuro Oncol. 9, 424\u2013429. https:\/\/doi.org\/10.1215\/15228517-2007-023 (2007).","journal-title":"Neuro Oncol."},{"key":"77228_CR22","doi-asserted-by":"publisher","DOI":"10.1111\/bpa.12788","author":"C Pouget","year":"2019","unstructured":"Pouget, C. et al. Ki-67 and MCM6 labeling indices are correlated with overall survival in anaplastic oligodendroglioma, IDH1-mutant and 1p\/19q-codeleted: a multicenter study from the French POLA network. Brain Pathol. https:\/\/doi.org\/10.1111\/bpa.12788 (2019).","journal-title":"Brain Pathol."},{"key":"77228_CR23","first-page":"471","volume":"36","author":"J Polivka Jr","year":"2016","unstructured":"Polivka, J. Jr. et al. Co-deletion of 1p\/19q as prognostic and predictive biomarker for patients in west bohemia with anaplastic oligodendroglioma. Anticancer Res. 36, 471\u2013476 (2016).","journal-title":"Anticancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77228-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77228-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77228-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,6]],"date-time":"2022-12-06T23:21:39Z","timestamp":1670368899000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-020-77228-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,19]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,12]]}},"alternative-id":["77228"],"URL":"https:\/\/doi.org\/10.1038\/s41598-020-77228-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,19]]},"assertion":[{"value":"30 July 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20162"}}